menu
    • menu
    [{"orgOrder":0,"company":"ReViral","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sisunatovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReViral \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ Not Applicable"},{"orgOrder":0,"company":"ReViral","sponsor":"CR-CP Life Science Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Series C Financing","leadProduct":"Sisunatovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"ReViral \/ CR-CP Life Science Fund","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ CR-CP Life Science Fund"},{"orgOrder":0,"company":"LianBio","sponsor":"ReViral","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Sisunatovir","moa":"RSV fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LianBio","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"LianBio \/ ReViral","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ ReViral"},{"orgOrder":0,"company":"ReViral","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sisunatovir","moa":"RSV fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ReViral \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ Not Applicable"},{"orgOrder":0,"company":"ReViral","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Sisunatovir","moa":"RSV fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"ReViral \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ Pfizer"},{"orgOrder":0,"company":"ReViral","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Sisunatovir","moa":"RSV fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"ReViral \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ Pfizer"},{"orgOrder":0,"company":"LianBio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Sisunatovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LianBio","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"LianBio \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ Pfizer"}]

    Find Clinical Drug Pipeline Developments & Deals for Sisunatovir

    Menu

    Sisunatovir

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LianBio

                            China arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            LianBio

                            China arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $155.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland ...

                            Details : RV521 (sisunatovir) is an investigational orally administered fusion inhibitor designed to block RSV replication by inhibiting F-mediated fusion with the host cell. Sisunatovir is being evaluated for the potential treatment of RSV infection in pediatric ...

                            Brand Name : RV521

                            Molecule Type : Small molecule

                            Upfront Cash : $20.0 million

                            December 19, 2022

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $155.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pfizer Completes Acquisition of ReViral

                            Details : ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including RV521 (sisunatovir), an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.

                            Brand Name : RV521

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 09, 2022

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

                            Details : Proposed acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host...

                            Brand Name : RV521

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 07, 2022

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clin...

                            Details : REVIRAL1 study evaluate safety, tolerability, pharmacokinetic profile, antiviral effects, and clinical effect of single and multiple oral doses of sisunatovir in healthy infants between ages of 1 and 36 months hospitalized with RSV lower respiratory trac...

                            Brand Name : RV521

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 16, 2021

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            LianBio

                            China arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            LianBio

                            China arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : ReViral

                            Deal Size : $119.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisuna...

                            Details : Sisunatovir is ReViral’s lead small molecule for the treatment of RSV, currently in Phase 2 clinical studies in pediatric and adult immunocompromised patient populations.

                            Brand Name : RV521

                            Molecule Type : Small molecule

                            Upfront Cash : $14.0 million

                            March 02, 2021

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : ReViral

                            Deal Size : $119.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : CR-CP Life Science Fund

                            Deal Size : $44.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            ReViral Raises $44 Million in Series C Financing

                            Details : The proceeds from the financing will be used to support Phase 2 clinical development for sisunatovir, ReViral's wholly-owned fusion protein inhibitor, and to progress our N-protein replication inhibitor program into Phase 1.

                            Brand Name : RV521

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 25, 2020

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : CR-CP Life Science Fund

                            Deal Size : $44.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            ReViral

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory S...

                            Details : Sisunatovir is the company’s most advanced product candidate, with two international multicentre Phase 2 clinical studies recently initiated in pediatric and high-risk adult patient populations.

                            Brand Name : RV521

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 04, 2020

                            Lead Product(s) : Sisunatovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth